Loading...
•
Mar 31
Stryker Q1 2025 Earnings Report
Stryker reported strong performance in Q1 2025 with double-digit organic sales growth and increased adjusted earnings.
Key Takeaways
Stryker delivered solid Q1 2025 results, driven by continued demand for MedSurg and Orthopaedics, with revenue reaching $5.9B and adjusted EPS up 13.6% year-over-year.
Total revenue grew 11.9% year-over-year to $5.866 billion.
Organic net sales rose 10.1%, led by strong unit volume growth.
Adjusted EPS increased to $2.84, up 13.6% from Q1 2024.
Net income declined to $654 million due to acquisition and restructuring costs.
Stryker
Stryker
Stryker Revenue by Segment
Revenue by Segment
MedSurg and Neurotechnology Revenue
CapyFin.comOrthopaedics Revenue
CapyFin.com Forward Guidance
Stryker raised its full-year 2025 organic net sales growth guidance while reaffirming adjusted EPS guidance inclusive of acquisition and tariff impacts.
Positive Outlook
- Organic net sales growth guidance raised to 8.5%–9.5%.
- Strong capital product demand supports growth outlook.
- Continued commercial execution driving performance.
- Pricing impact remains modestly favorable.
- Inari acquisition expected to add long-term value.
Challenges Ahead
- Full-year EPS guidance lowered due to acquisition dilution.
- $200 million expected tariff impact.
- Foreign exchange expected to slightly reduce results.
- Ongoing structural optimization costs.
- Regulatory and compliance costs continue to impact earnings.
Revenue & Expenses
Visualization of income flow from segment revenue to net income